Innovations for Next-Generation Antibody-Drug Conjugates

Discover the groundbreaking insights in Innovations for Next-Generation Antibody-Drug Conjugates by Springer Nature Switzerland AG. Published in 2019, this comprehensive paperback spans 357 pages and serves as an essential resource for researchers and professionals in the field of oncology. This book primarily focuses on antibody-drug conjugates (ADCs) for solid tumors, providing in-depth analysis and innovative strategies for their application. In the final chapter, the author delves into the exciting potential of ADCs for treating various other diseases, highlighting the therapeutic rationale behind these powerful treatments. By conjugating small molecules to antibodies or other targeting moieties, ADCs aim to deliver medications precisely where they are needed, minimizing impact on normal tissues. Enhance your understanding of this cutting-edge field with this essential read for anyone involved in cancer therapy and drug development.